<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-5287-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VINCRISTIN SULPH. 1MG-ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VINCRISTINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        159.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HOSPIRA AUSTRALIA " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HOSPIRA AUSTRALIA 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HOSPIRA UK LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01CA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vincristine Sulphate is an anti-cancer medicine. Treatment with an anti-cancer medicine is sometimes called cancer chemotherapy.</p><p>&nbsp;</p><p>Vincristine Sulphate solution for injection is used in the treatment of cancers of the blood (e.g. leukaemia or lymphomas), breast, head and neck or lung. It may be used to treat multiple myeloma (a cancer of plasma cells) and it may also be used in the treatment of some cancers in children. It may be used in a blood disorder known as idiopathic thrombocytopenic purpura (ITP) after other treatments have not been successful.</p><p>&nbsp;</p><p>Vincristine Sulphate solution for injection may be given alone or in combination with other anti-cancer medicines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Vincristine Sulphate solution for injection must never be injected intrathecally (into the spine).</strong></p><p><strong>Vincristine Sulphate solution for injection is for intravenous use only.</strong></p><p>&nbsp;</p><p><strong>Do not use Vincristine Sulphate solution for injection</strong></p><ul><li>if you are allergic to vincristine sulphate or any of the other ingredients of this medicine (listed in section 6)</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have Charcot-Marie-Tooth syndrome (disease which causes weakness in the leg muscles)</p><ul><li>if you have an infection that is not being treated</li></ul><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p><strong>This medicine should only be given by healthcare professionals experienced in the use of vincristine or other similar medicines.</strong></p><p>&nbsp;</p><p>Talk to your doctor, pharmacist or nurse before using Vincristine Sulphate solution for injection.</p><ul><li><strong>to make sure that this medicine is only given to you through a vein (it should not be given by any other route). If you notice any pain during, or soon after the injection is given, tell your doctor or nurse immediately</strong></li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a mental or nervous system disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver trouble (can increase the severity of side effects that you may experience)</p><ul><li>if you have kidney cancer</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are having radiotherapy</p><ul><li>if you have breathing problems. Acute shortness of breath and severe bronchospasm have been reported following the administration of vinca alkaloids. Vincristine Sulphate is an example of a vinca alkaloid</li><li>if you have a low white blood cell count measured on blood test</li><li>if you have an infection</li></ul><p>&nbsp;</p><p>Special care is also needed if you are elderly.</p><p>&nbsp;</p><p><strong>Other medicines and Vincristine Sulphate solution for injection</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>There may be interactions between vincristine sulphate and other medicines such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; isoniazid (medicine used to treat tuberculosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mitomycin-C (anti-cancer medicine)</p><ul><li>azole antifungals (a group of medicines used to treat fungal infections e.g. itraconazole, posaconazole, fluconazole, isavuconazole or voriconazole)</li><li>ketoconazole (used to treat Cushing&rsquo;s syndrome, a disease characterised by an excess production of the hormone cortisol)</li><li>L-asparaginase (used for treating some types of cancer)</li><li>dactinomycin (used for treating some types of cancer)</li><li>some anti-cancer drugs (e.g. containing platinum) that may cause problems with hearing or balance</li><li>medicines which cause problems with passing water (urine). These should be stopped before you start treatment with vincristine sulphate</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines which cause problems with your nervous system e.g. walking difficulties, pins and needle or numbness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaccines known as &ldquo;live&rdquo; vaccines. Vincristine sulphate lowers the immune defences if used at the same time with this type of vaccine, it may cause severe infections. Check with your healthcare team how long you should wait prior to administration of live vaccines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for the treatment of low number of white blood cells (granulocyte-colony stimulating factors (G-CSFs)). Using G-CSFs at the same time with vincristine sulphate may decrease production of blood cells in the bone marrow (myelosuppression). Your healthcare team will ensure G-CSFs are started following the recommended period after vincristine treatment.</p><p>&nbsp;</p><p>Phenytoin (medicine used to control fits) may not work as well when vincristine sulphate is used, so blood levels of phenytoin will need to be monitored.</p><p>&nbsp;</p><p>Methotrexate used in the treatment of cancer may work better when used with vincristine sulphate.</p><p>&nbsp;</p><p>St. John&rsquo;s wort used with vincristine sulphate should be given cautiously.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Women of childbearing potential should use appropriate contraception methods during treatment and for at least 7 months following the last dose of vincristine sulphate.</p><p><strong>&nbsp;</strong></p><p>Men are advised to use appropriate contraception methods during treatment and for at least 4 months following the last dose of vincristine sulphate.</p><p>&nbsp;</p><p>Because of the possibility of serious reactions to the nursing child, mothers are advised not to breast-feed during treatment and for 1 month following last dose of vincristine sulphate.</p><p>&nbsp;</p><p>Treatment with vincristine sulphate can affect your fertility. Men and women who may want to have children after treatment with vincristine sulphate are recommended to discuss with their doctor options for fertility preservation.</p><p>&nbsp;</p><p>Talk to your doctor about contraceptive methods that are right for you and your partner.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Do not drive or use machines if you experience any side effect which may lessen your ability to do so.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>This medicine must be given ONLY through a vein either by intravenous injection (IV) or infusion (IV)</strong> <strong>given by drip into a vein. </strong><strong>Never be injected intrathecally (into the spine). </strong></p><p>&nbsp;</p><p>Vincristine sulphate is usually given once a week.</p><p>&nbsp;</p><p>Vincristine sulphate is an irritant, if it accidentally gets into your eye tell your doctor or nurse immediately so that it may be washed out.</p><p>&nbsp;</p><p>You may be given medicines to prevent constipation during treatment with vincristine sulphate.</p><p>&nbsp;</p><p><strong>Dosage</strong></p><p>Your doctor will work out the correct dose of vincristine sulphate for you and how often it must be given.&nbsp;</p><p>&nbsp;</p><p>The dose will depend on your medical condition, your size and how well your liver is working. Your doctor will tell how well your liver is working using a blood sample.</p><p>&nbsp;</p><p><strong>If you are given too much or too little Vincristine Sulphate solution for injection</strong></p><p>This medicine will be given to you in a hospital, under the supervision of a doctor. It is unlikely that you will be given too little or too much, however, tell your doctor or nurse if you have any concerns.</p><p><strong>&nbsp;</strong></p><p>If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can have side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>If any of the following happen, tell your doctor immediately:</strong></p><ul><li><strong>s</strong>evere allergic reaction &ndash; you may experience a sudden itchy rash (hives), swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing), and you may feel you are going to faint.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or swelling at the injection site during or immediately after the injection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe chest pains possibly radiating to the jaw or arm, sweating, breathlessness and nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe breathing problems or shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms suggestive of sepsis &ndash; these may include a high fever or low temperature, shivering, fast heartbeat, rapid breathing, feeling faint, skin changes (cold, clammy and mottled or pale), altered mental state such as confusion or disorientation, decreased urination, nausea, vomiting etc. The presence of a few or several of these symptoms coupled with a rapid deterioration of general condition might indicate sepsis and immediate medical attention should be sought.</p><p>&nbsp;</p><p>These are serious side effects. You may need urgent medical attention.</p><p>&nbsp;</p><p><strong>If any of the following happen, tell your doctor as soon as possible:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common side effects:</strong> <strong>may affect more than 1 in 10 people</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in blood platelets, which increases risk of bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in red blood cells which can make the skin pale and cause tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness or pins and needles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation, stomach cramps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick or feeling sick</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness or muscle wasting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in bones</p><ul><li>significant weight loss</li></ul><p>&nbsp;</p><p><strong>Common side effects:</strong> <strong>may affect up to 1 in 10 people</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in jaw and throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with passing water (more or less urine than normal, or pain when passing urine)</p><p>&nbsp;</p><p><strong>Uncommon side effects:</strong> <strong>may affect up to 1 in 100 people</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coma</p><p><strong>&nbsp;</strong></p><p><strong>Not Known:</strong> <strong>frequency cannot be estimated from the available data</strong></p><p>&nbsp;</p><ul><li>infections</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, sore throat, skin rashes, or sores on your body and mouth ulcers (may indicate a drop in white blood cells)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unexpected bruises</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; elevated blood uric acid levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; paralysis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsions (fits)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of reflexes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders of brain function</p><ul><li>difficulty in walking</li><li>difficulty with speech</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual eye movements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; worsening eyesight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deafness or hearing loss</p><ul><li>build up of plaque in arteries</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised or lowered blood pressure</p><ul><li>mild breathing problems</li><li>tiredness</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bladder problems</p><ul><li>soreness around the injection site after the injection</li></ul><p>&nbsp;</p><p>Vincristine sulphate may lead to changes in your blood cells, including a type of anaemia in which red blood cells are destroyed (haemolytic anaemia). Your doctor may take blood samples to monitor for these and also to check how well your liver is working.</p><p>&nbsp;</p><p>There have been reports of other malignancies (cancers) occurring at a later date after vincristine sulphate has been used in combination with other anti-cancer drugs. This happens rarely.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>To Report side effects:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p><strong>&nbsp;</strong></p><p><strong>Expiry</strong></p><p>24 months.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the vial label and carton after &#39;EXP&#39;.&nbsp; Where only a month and year is stated, the expiry date refers to the last day of that month.</p><p>&nbsp;</p><p><strong>Storage Conditions</strong></p><p>Store in a refrigerator (2 &ordm;C &ndash; 8 &ordm;C). The vials should be kept in the outer carton, in order to protect from light.</p><p>&nbsp;</p><p>Do not use this medicine if you notice evidence of precipitation or any other particulate matter.</p><p>&nbsp;</p><p>Syringes, containers, absorbent materials, solution and any other contaminated material should be placed in a thick plastic bag or other impenetrable container and destroyed by burning. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is vincristine sulphate. Each millilitre (ml) of solution contains 1 milligram (mg) of vincristine sulphate. Each 2 ml vial contains 2 mg of vincristine sulphate.</p><p>&nbsp;</p><p>The other ingredients are mannitol and water for injections.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vincristine Sulphate solution for injection is a colourless solution which comes in glass containers called vials. 

It may be supplied in packs containing: 
5 x 1 mg/1ml vials, 
5 x 2 mg/2 ml vials 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing authorisation holder </strong></p><p>Hospira UK Limited, United Kingdom.</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Hospira Australia Pty Ltd, MULGRAVE, Australia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">سلفات فينكريستين هو دواء مضاد للسرطان. وفي بعض الأحيان، يُطلق على العلاج باستخدام دواء مضاد للسرطان مصطلح العلاج الكيميائي للسرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم محلول سلفات فينكريستين المخصص للحقن في علاج سرطانات الدم (مثل ابيضاض الدم أو سرطانات الغدد الليمفاوية) أو الثدي أو الرأس والرقبة أو الرئة.&nbsp; يمكن استخدامه لعلاج الورم النقوي المتعدد (سرطان يصيب خلايا البلازما)، ويمكن أيضًا استخدامه لعلاج بعض أنواع السرطانات لدى الأطفال. ويمكن استخدامه في حالة الإصابة باضطراب الدم الذي يُعرف بفرفرية نقص الصفيحات مجهولة السبب (ITP) بعد عدم نجاح العلاج باستخدام طرق علاجية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إعطاء محلول سلفات فينكريستين المخصص للحقن بمفرده أو بالتزامن مع أدوية أخرى مضادة للسرطان.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب ألا يُحقن محلول سلفات فينكريستين المخصص للحقن داخل القراب (داخل العمود الفقري) أبدًا.</strong></p><p dir="RTL"><strong>محلول سلفات فينكريستين </strong><strong>ال</strong><strong>مخصص للحقن يُستخدم عبر الوريد فقط.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استعمال محلول سلفات فينكريستين المخصص للحقن</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بحساسية تجاه سلفات فينكريستين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمتلازمة شاركو-ماري-توث (مرض يسبب ضعفًا في عضلات الساق)</p><ul><li dir="RTL">إذا كنت مصابًا بعدوى لا تخضع للمعالجة</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال محلول سلفات فينكريستين المخصص للحقن</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ينبغي</strong><strong> </strong><strong>عدم إعطاء هذا الدواء إلا من قبل أخصائيي الرعاية الصحية من ذوي الخبرة في استخدام فينكريستين أو أدوية أخرى مماثلة.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل استخدام محلول سلفات فينكريستين المخصص للحقن</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL"><strong>للتأكد من أن هذا الدواء يُعطى لك عبر أحد الأوردة فقط (ينبغي ألا يُعطى عبر أي مسار آخر). إذا شعرت بأي ألم أثناء الحقن أو بعده بوقت قصير، فأبلغ طبيبك أو الممرضة بذلك على الفور</strong></li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا باضطراب عقلي أو في الجهاز العصبي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلة في الكبد (يمكن أن تزيد من حدة الأعراض الجانبية التي قد تتعرض لها)</p><ul><li dir="RTL">إذا كنت مصابًا بسرطان الكلى</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع للعلاج الإشعاعي</p><ul><li dir="RTL">إذا كنت تعاني من مشكلات في التنفس. تم الإبلاغ عن حالات من ضيق التنفس الحاد والتشنج القصبي شديد الحدة بعد إعطاء قلويات الفينكا. سلفات فينكريستين مثال على قلويات الفينكا.</li><li dir="RTL">إذا أظهر فحص الدم أنك تعاني من انخفاض تعداد خلايا الدم البيضاء</li><li dir="RTL">إذا كنت مصابًا بعدوى</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">يجب كذلك توخي الحذر بشكل خاص إذا كنت مسنًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث تفاعلات بين سلفات فينكريستين والأدوية الأخرى مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أيزونيازيد (دواء يستخدم لعلاج السل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميتومايسين-سي (دواء مضاد للسرطان)</p><ul><li dir="RTL">مضادات الفطريات الآزولية (مجموعة من الأدوية المستخدمة لعلاج العدوى الفطرية مثل إيتراكونازول، أو بوساكونازول، أو فلوكونازول، أو إيزافوكونازول، أو فوريكونازول)</li><li dir="RTL">&nbsp;كيتوكونازول (يستخدم لعلاج متلازمة كوشينج، وهو مرض يتسم بإنتاج زائد لهرمون الكورتيزول)</li><li dir="RTL">ل-أسباراجيناز (يستخدم لعلاج بعض أنواع السرطان)</li><li dir="RTL">داكتينومايسين (يستخدم لعلاج بعض أنواع السرطان)</li><li dir="RTL">بعض العقاقير المضادة للسرطان (مثل التي تحتوي على البلاتين) التي يمكن أن تتسبب في حدوث مشكلات في السمع أو التوازن</li><li dir="RTL">الأدوية التي تتسبب في حدوث مشكلات في التبول.&nbsp; ينبغي إيقاف استخدام تلك الأدوية قبل أن تبدأ العلاج بسلفات فينكريستين</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تتسبب في حدوث مشكلات في الجهاز العصبي، مثل صعوبات المشي والشعور بالشكشكة والوخز أو الخدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اللقاحات المعروفة باللقاحات &quot;الحية&quot;. يؤدي فينكريستين سلفات إلى خفض الدفاعات المناعية عند استخدامه في الوقت نفسه مع هذا النوع من اللقاحات؛ وقد يسبب حالات عدوى شديدة. استشر فريق رعايتك الصحية لمعرفة المدة التي ينبغي لك انتظارها قبل تلقي اللقاحات الحية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج انخفاض عدد خلايا الدم البيضاء (عوامل تحفيز مستعمرات الخلايا المحببة (G-CSF)). قد يؤدي تلقي عوامل تحفيز مستعمرات الخلايا المحببة في الوقت نفسه مع فينكريستين سلفات إلى خفض إنتاج خلايا الدم في نخاع العظام (كبت نقي العظم). لذا سيحرص فريق رعايتك الصحية على بدء تلقيك عوامل تحفيز مستعمرات الخلايا المحببة بعد انقضاء المدة الموصى بها بعد تلقيك علاج فينكريستين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن ألا يعمل فينيتوين (دواء يستخدم للتحكم في النوبات) كما ينبغي عند استخدام سلفات فينكريستين بشكل متزامن معه، لذلك سيلزم مراقبة مستويات فينيتوين في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يعمل ميثوتريكسات، المستخدم في علاج السرطان، بشكل أفضل عند استخدامه مع سلفات فينكريستين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي إعطاء نبتة سانت جون المستخدمة مع سلفات فينكريستين بحذر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي على السيدات القادرات على الإنجاب أن يستخدمن وسائل مناسبة لمنع الحمل أثناء العلاج بسلفات فينكريستين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير محلول سلفات فينكريستين المخصص للحقن على القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تقم بالقيادة أو استخدام الآلات إذا أصبت بأي آثار جانبية قد تحد من قدرتك على فعل ذلك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>يجب ألا </strong><strong>يُعطى هذا الدواء إلا عن طريق الوريد </strong><strong>إما عن طريق الحقن عبر الوريد </strong><strong>(</strong><strong>IV</strong><strong>)</strong><strong> أو التسريب (عبر الوريد) </strong><strong>عن طريق </strong><strong>التنقيط في أحد الأوردة. يجب ألا يُحقن داخل القراب (داخل العمود الفقري) أبدًا. </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">عادةً ما يُعطى سلفات فينكريستين بمعدل مرة واحدة أسبوعيًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعتبر سلفات فينكريستين مادة مهيجة، ولذلك إذا دخل إلى عينيك عن طريق الخطأ يجب عليك إبلاغ طبيبك أو الممرضة بذلك على الفور حتى يتم غسله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتم إعطاؤك أدوية لمنع الإصابة بالإمساك أثناء العلاج بسلفات فينكريستين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">سيحدد طبيبك مقدار الجرعة الصحيحة لك من سلفات فينكريستين وكذلك المعدل الواجب إعطاؤك الدواء وفقًا له.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">وسيعتمد مقدار الجرعة على حالتك الطبية وحجمك ومدى كفاءة عمل كبدك. سيتمكن طبيبك من معرفة مدى كفاءة عمل كبدك باستخدام عينة دم يتم سحبها منك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من محلول سلفات فينكريستين المخصص للحقن</strong></p><p dir="RTL"><strong>في حالة إعطاؤك كمية أكبر أو أقل مما ينبغي من محلول سلفات فينكريستين المخصص للحقن</strong></p><p dir="RTL">سيتم إعطاء هذا الدواء لك في مستشفى، وتحت إشراف طبيب.&nbsp; ومن غير المرجح أن يتم إعطاؤك كمية أقل أو أكبر مما ينبغي، ومع ذلك، أخبر طبيبك أو الممرضة إذا كانت لديك أي مخاوف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك المزيد من الأسئلة حول استخدام هذا الدواء، فاسأل طبيبك.</p><p dir="RTL"><strong>&nbsp;</strong></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن تكون لهذا الدواء أعراض جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا حدث أي مما يلي، فأخبر طبيبك على الفور:</strong></p><ul><li dir="RTL">تفاعل حساسية شديد &ndash; قد تصاب بطفح جلدي مفاجئ مثير للحكة&nbsp; وتورم في اليدين أو القدمين أو الكاحلين أو الوجه أو الشفتين أو الفم أو الحلق (مما قد يسبب صعوبة في البلع أو التنفس) وقد تشعر بأنك على وشك الإصابة بالإغماء.</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو تورم في موضع الحقن، أثناء الحقن أو بعده مباشرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام شديدة في الصدر يحتمل أن تمتد إلى الفك أو الذراع، العرق، انقطاع النفس والغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات شديدة في التنفس أو ضيق التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأعراض التي تشير إلى حدوث إنتان &ndash; وقد تشمل الإصابة بحمى مرتفعة أو انخفاض درجة الحرارة أو الارتعاش أو تسارع ضربات القلب أو سرعة التنفس أو الشعور بالضعف أو حدوث تغيرات في الجلد (البرودة أو الرطوبة والتبقيع أو الشحوب) أو تغير الحالة العقلية مثل الإصابة بالارتباك أو التوهان أو انخفاض معدل التبول أو الغثيان أو القيء، إلخ. إن ظهور القليل من هذه الأعراض أو الكثير منها مصحوبة بتدهور سريع للحالة العامة قد يشير إلى حدوث إنتان وينبغي حينها التماس العناية الطبية الفورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تُعد هذه الآثار الجانبية خطيرة. وقد تحتاج إلى عناية طبية عاجلة في حال حدوثها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا حدث أي مما يلي، فأخبر طبيبك في أسرع وقت ممكن:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض جانبية شائعة جدًا: قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفائح الدموية مما يزيد من خطر النزيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم الحمراء مما قد يجعل الجلد شاحبًا ويسبب التعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخدر أو الإحساس بالشكشكة والوخز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك وتشنجات المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ أو الشعور برغبة في التقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات أو هزال العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في العظام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خسارة كبيرة في الوزن</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية شائعة: قد تصيب</strong><strong> ما يصل إلى شخص واحد من بين كل ١٠ أشخاص</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم في الفك والحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في التبول (زيادة أو قلة البول عن المعدل الطبيعي، أو الشعور بألم عند التبول)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية غير شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغيبوبة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض جانبية معدل تكرارها غير معروف: لا يمكن تقدير معدل التكرار من البيانات المتوفرة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><ul><li dir="RTL">العدوى</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى أو التهاب الحلق أو الطفح الجلدي أو ظهور تقرحات على جسمك وقرح بالفم (يمكن أن تشير إلى انخفاض في تعداد خلايا الدم البيضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكدمات غير المتوقعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات حمض اليوريك في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشلل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات (النوبات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان ردود الفعل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><ul><li dir="RTL">اضطرابات في وظائف الدماغ</li><li dir="RTL">صعوبة المشي</li><li dir="RTL">صعوبة التحدث</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات عين غير اعتيادية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور البصر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصمم أو فقدان السمع</p><ul><li dir="RTL">تراكم اللويحات في الشرايين</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع أو انخفاض ضغط الدم</p><ul><li dir="RTL">مشكلات خفيفة في التنفس</li><li dir="RTL">التعب</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر</p><ul><li dir="RTL">مشكلات في المثانة</li><li dir="RTL">الشعور بألم في المنطقة المحيطة بموضع الحقن بعد تلقي الحقن</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يتسبب سلفات فينكريستين في حدوث تغيرات في خلايا دمك، بما في ذلك الإصابة بأحد أنواع فقر الدم يتم فيه تدمير خلايا الدم الحمراء (فقر الدم الانحلالي). قد يقوم طبيبك بسحب عينات دم منك لرصد هذه التغيرات، وكذلك للتحقق من مدى كفاءة عمل كبدك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لقد وردت تقارير بشأن حدوث خباثات (سرطانات) أخرى في وقتٍ لاحق بعد استخدام سلفات فينكريستين بالتزامن مع عقاقير أخرى مضادة للسرطان. وهذا نادرًا ما يحدث.</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي بشأنها. يشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">للإبلاغ عن الأعراض الجانبية:</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>مركز الاتصال&nbsp; الموحد: 19999</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>الموقع الإلكتروني: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong>:</p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انتهاء الصلاحية</strong></p><p dir="RTL">صلاحية المستحضر: ٢٤ شهرًا.<br />&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصق القارورة والعبوة الكرتونية بعد الرمز &quot;EXP&quot;.&nbsp; في حالة ذكر الشهر والعام فقط، فإن تاريخ انتهاء الصلاحية يشير إلى آخر يوم في الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ظروف التخزين</strong></p><p dir="RTL">احفظه في مُبرِّد (٢-٨ درجات مئوية). ينبغي حفظ القوارير في العبوة الكرتونية الخارجية من أجل حمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي دليل على حدوث ترسيب أو أي جزيئات دقيقة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي وضع المحاقن والحاويات والمواد الماصة والمحلول وأي مادة ملوثة أخرى في كيس بلاستيكي سميك أو حاوية أخرى غير قابلة للاختراق والتخلص منها عبر حرقها. لا تتخلص من أي أدوية عبر مياه الصرف الصحي أو مع النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المادة الفعالة هي سلفات فينكريستين. يحتوي كل ملليلتر (مل) من المحلول على ١ مليجرام (ملجم) من سلفات فينكريستين. تحتوي كل قارورة ٢ مل على ٢ ملجم من سلفات فينكريستين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي مانيتول وماء للحقن.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">محلول سلفات فينكريستين المخصص للحقن هو محلول صاف عديم اللون يأتي في حاويات زجاجية تُسمى قوارير.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويمكن أن يتم توفيره في عبوات تحتوي على:</p><p dir="RTL">٥ قوارير x&rlm; ١ ملجم/١ مل</p><p dir="RTL">٥ قوارير x&rlm; ٢ ملجم/٢ مل</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Hospira UK Limited, United Kingdom، المملكة المتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التصنيع:</strong></p><p dir="RTL">Hospira Australia Pty Ltd, MULGRAVE, Australia، أستراليا</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر/أيلول ٢٠٢٤
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vincristine Sulphate 1 mg/ml solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 1 ml contains 1 mg of vincristine sulphate 	
Each 2 ml contains 2 mg of vincristine sulphate

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection

A sterile, colourless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vincristine Sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of:</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Malignant lymphomas, including Hodgkin&#39;s disease and non-Hodgkin&#39;s lymphomas.</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Multiple myeloma.</p><p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Solid tumours, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas.&nbsp;</p><p>&nbsp;</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paediatric solid tumours, including Ewing&#39;s sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, Wilms&#39; tumour, retinoblastoma and medulloblastoma.</p><p>&nbsp;</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Idiopathic thrombocytopenic purpura. Patients with true ITP refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to vincristine sulphate but the medicinal product is not recommended as primary treatment of this disorder.&nbsp; Recommended weekly doses of vincristine sulphate given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any beneficial results with additional doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The following dosage regimens have been used:</p><p>&nbsp;</p><p><strong>Adults:</strong> The drug is administered intravenously at weekly intervals. The recommended dose is 1.4 to 1.5 mg/m<sup>2</sup> up to a maximum weekly dose of 2 mg.</p><p>&nbsp;</p><p><strong>Children:</strong> The suggested dose is 1.4 to 2 mg/m<sup>2</sup> given on a weekly basis with a maximum weekly dose of 2 mg. For children weighing 10 kg or less the starting dose should be 0.05 mg/kg administered as a weekly intravenous injection.</p><p>&nbsp;</p><p><strong>Elderly:</strong> The normal adult dose is still appropriate in the elderly.</p><p>&nbsp;</p><p><strong>Hepatic Impairment: </strong>Because of the hepatic metabolism and biliary excretion of vincristine sulphate, reduced doses are recommended in patients with obstructive jaundice or other hepatic impairment. Patients with liver disease sufficient to decrease biliary excretion may experience an increase in the severity of side-effects. A 50 per cent reduction in the dose of vincristine sulphate is recommended for patients having a direct serum bilirubin value above 3 mg/100 ml (51 micromol/l) (see section 4.4).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Precautions to be taken before handling or administering the medicinal product.</p><p>&nbsp;</p><p>This preparation is for intravenous (IV) use only. It should only be administered by individuals experienced in vincristine administration.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>FOR INTRAVENOUS USE ONLY</strong></p><p>FATAL IF GIVEN BY ANY OTHER ROUTE</p></td></tr></tbody></table><p>&nbsp;</p><p>Can be fatal if administered intrathecally (see sections&nbsp;4.3 and 4.4). See section 4.4 for use for the treatment of patients accidentally given intrathecal vincristine sulphate.</p><p>&nbsp;</p><p>Vincristine sulphate is administered by intravenous infusion at weekly intervals.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Great care should be exercised in calculating and administering the dose, as overdosage may be extremely serious or even fatal. The calculated dose of the vincristine solution should be administered ONLY through a vein either by intravenous injection or infusion (IV) according to the treatment protocol and under constant supervision for signs of extravasation. The dose should not be increased beyond the level which produces therapeutic benefit. Individual doses should not exceed 2 mg; and white cell counts should be carried out before and after giving each dose.</p><p>&nbsp;</p><p><em>Intravenous injection</em></p><p>Direct injection into the vein may be completed in about one minute.</p><p>&nbsp;</p><p><em>Intravenous infusion</em></p><p>The diluted vincristine sulphate injection may be infused via a flexible plastic container (e.g.: infusion bag) either directly into an intravenous catheter/needle or into a running intravenous infusion (see section&nbsp;6.2). It is recommended to administer the solution over 5 to 10 minutes after dilution in a 50 ml infusion bag (50 ml sodium chloride 9 mg/ml (0.9%) solution for injection or glucose 50&nbsp;mg/ml (5%) solution for injection). After administration the vein must be flushed through thoroughly.&nbsp; Care should be taken to avoid extravasation as this may cause local ulceration.</p><p>&nbsp;</p><p>Caution: If leakage into surrounding tissue should occur during intravenous administration of vincristine sulphate, it may cause considerable irritation. The injection should be discontinued immediately and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage help to disperse the drug and are thought to minimise discomfort and the possibility of cellulitis.</p><p>&nbsp;</p><p>With the vial presentations, do not add extra fluid to the vial prior to removal of the dose. Withdraw the solution of vincristine sulphate into an accurate dry syringe, measuring the dose carefully. Do not add extra fluid to the vial in an attempt to empty it completely.</p><p>&nbsp;</p><p>TO REDUCE THE POTENTIAL FOR FATAL MEDICATION ERRORS DUE TO INCORRECT ROUTE OF ADMINISTRATION, VINCRISTINE SULPHATE INJECTION IS RECOMMENDED TO BE DILUTED IN A FLEXIBLE PLASTIC CONTAINER AND PROMINENTLY LABELLED AS INDICATED<strong> FOR INTRAVENOUS USE ONLY &ndash; FATAL IF GIVEN BY OTHER ROUTES </strong>(see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>Because of the narrow range between therapeutic and toxic levels and variations in response, the dosage must always be adjusted to the individual.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For instructions on dilution of the medicinal product before administration, see section 6.6<strong>.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Intrathecal administration of vincristine sulphate is usually fatal. For intravenous use only (see section 4.4).

Hypersensitivity to vincristine sulphate or to any of the excipients listed in section 6.1.

Patients with the demyelinating form of Charcot-Marie-Tooth syndrome should not be given vincristine sulphate.

Careful notice should also be given to those conditions listed in section 4.4.  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This preparation is for intravenous use only (see sections 4.2 and 4.3). &nbsp;Can be fatal if administered intrathecally.</p><p>It should be administered by physicians experienced in the administration of vincristine sulphate. Vincristine sulphate should not be given by intrathecal, intramuscular or subcutaneous injection.</p><p>&nbsp;</p><p>Syringes containing this product should be labelled &lsquo;VINCRISTINE FOR INTRAVENOUS USE ONLY. FATAL IF GIVEN BY OTHER ROUTES&rsquo;.</p><p><em>&nbsp;</em></p><p><em>Emergency Treatment of accidental intrathecal administration:</em></p><p>After inadvertent intrathecal administration, immediate neurosurgical intervention is required in order to prevent ascending paralysis leading to death. In a very small number of patients, life-threatening paralysis and subsequent death was averted but resulted in devastating neurological sequelae, with limited recovery afterwards.</p><p>&nbsp;</p><p>Based on the published management of these survival cases, if vincristine sulphate is mistakenly given by the intrathecal route, the following treatment should be initiated <strong>immediately after the injection:</strong></p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Removal of as much cerebrospinal fluid (CSF) as is safely possible through the lumbar access.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insertion of an epidural catheter into the subarachnoid space via the intervertebral space above initial lumbar access and CSF irrigation with lactated Ringer&rsquo;s solution. Fresh frozen plasma should be requested and, when available, 25 ml should be added to every 1 litre of lactated Ringer&rsquo;s solution.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insertion of an intraventricular drain or catheter by a neurosurgeon and continuation of CSF irrigation with fluid removal through the lumbar access connected to a closed drainage system. Lactated Ringer&rsquo;s solution should be given by continuous infusion at 150 ml/h, or at a rate of 75 ml/h when fresh frozen plasma has been added as above.</p><p>&nbsp;</p><p>The rate of infusion should be adjusted to maintain a spinal fluid protein level of 150 mg/dl.</p><p>&nbsp;</p><p>The following measures have also been used in addition but may not be essential:</p><p>&nbsp;</p><p>Folinic acid has been administered intravenously as a 100 mg bolus and then infused at a rate of 25 mg/h for 24 hours, then bolus doses of 25 mg 6-hourly for 1 week. Intravenous administration of glutamic acid 10 g over 24 hours, followed by 500 mg three times daily by mouth for one month. Pyridoxine has been given at a dose of 50 mg 8 hourly by intravenous infusion over 30 minutes. Their roles in the reduction of neurotoxicity are unclear.</p><p><strong>&nbsp;</strong></p><p>Vincristine Sulphate is a vesicant and may cause severe local reaction or extravasation, see <em>Caution</em> in section 4.2.&nbsp;</p><p><strong>&nbsp;</strong></p><p><u>Interaction with azole antifungals </u></p><p>Concomitant administration of azole antifungals with vincristine has been associated with neurotoxicity and other serious adverse reactions, including seizures, peripheral neuropathy, syndrome of inappropriate antidiuretic hormone secretion (SIADH), and paralytic ileus. Reserve azole antifungals for patients receiving vincristine who have no alternative antifungal treatment options (see section 4.5).</p><p><strong>&nbsp;</strong></p><p><u>Haematological</u></p><p>Granulocytopenia is less likely following therapy with vincristine sulphate than is the case with other oncolytic agents. It is usually neuromuscular rather than bone marrow toxicity that limits dosage. However, because of the possibility of granulocytopenia, both physician and patient should remain alert for signs of any complicating infection. If granulocytopenia or a complicating infection is present, then administration of the next dose of vincristine sulphate warrants careful consideration. On occasions, these infections may prove fatal.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>An increase in the severity of side-effects may be experienced by patients with liver disease sufficient to decrease biliary excretion (see section 4.2).</p><p>&nbsp;</p><p><u>Urate nephropathy</u></p><p>Acute uric acid nephropathy, which may occur after administration of oncolytic agents, has also been reported with vincristine sulphate.</p><p>&nbsp;</p><p><u>Neurological</u></p><p>As vincristine sulphate penetrates the blood-brain barrier poorly, additional agents and routes of administration may be required for central nervous system leukaemias.</p><p>&nbsp;</p><p>The neurotoxic effect of vincristine sulphate may be additive with other neurotoxic agents or increased by spinal cord irradiation and neurological disease. Elderly patients may be more susceptible to the neurotoxic effects of vincristine sulphate.</p><p>&nbsp;</p><p><u>Respiratory</u></p><p>Acute shortness of breath and severe bronchospasm have been reported following the administration of vinca alkaloids. These reactions have been encountered most frequently when the vinca alkaloid was used in combination with mitomycin-C (see section 4.5).</p><p>&nbsp;</p><p><u>Mutagenicity</u></p><p>Both in vivo and in vitro laboratory tests have failed to demonstrate conclusively that this product is mutagenic. Fertility following treatment with vincristine sulphate alone for malignant disease has not been studied in humans. Clinical reports of both male and female patients who received multiple-agent chemotherapy that included vincristine sulphate indicate that azoospermia and amenorrhoea can occur in post pubertal patients. Recovery occurred many months after completion of chemotherapy in some but not all patients. When the same treatment is administered to prepubertal patients, it is much less likely to cause permanent azoospermia and amenorrhoea.</p><p>&nbsp;</p><p><u>Secondary malignancies</u></p><p>Patients who received vincristine sulphate chemotherapy in combination with anticancer drugs known to be carcinogenic have developed second malignancies. The contributing role of vincristine sulphate in this development has not been determined. No evidence of carcinogenicity was found following intraperitoneal administration in rats and mice, although this study was limited.&nbsp;</p><p>&nbsp;</p><p><u>Eyes disorders</u></p><p>Care should be exercised to avoid accidental contamination of the eyes as vincristine sulphate is highly irritant and can cause corneal ulceration. The eye should be washed immediately and thoroughly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Isoniazid</u></p><p>The neurotoxicity of vincristine sulphate may be additive with that of isoniazid and other drugs acting on the nervous system.</p><p>&nbsp;</p><p><u>Mitomycin-C</u></p><p>Acute shortness of breath and severe bronchospasm have been reported following the administration of vinca alkaloids. These reactions have been encountered most frequently when the vinca alkaloid was used in combination with mitomycin-C and may be serious when there is pre-existing pulmonary dysfunction. The onset may be within minutes or several hours after the vinca is administered and may occur up to 2 weeks following the dose of mitomycin. Progressive dyspnoea, requiring chronic therapy, may occur. Vincristine sulphate should not be re-administered.</p><p>&nbsp;</p><p><u>Phenytoin</u></p><p>The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations, that included vincristine sulphate, have been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. Although the contribution of the vinca alkaloids has not been established, dosage adjustment of phenytoin, based on serial blood level monitoring, may need to be made when it is used in combination with vincristine sulphate.</p><p>&nbsp;</p><p><u>CYP 3A4 inhibitors/inducers</u></p><p>Caution should be exercised in patients concurrently taking drugs known to inhibit/induce drug metabolism by hepatic cytochrome P450 isoenzymes in the CYP 3A subfamily, or in patients with hepatic dysfunction (see section 4.2). &nbsp;Inhibitors like ketoconazole and inducers like St. John&rsquo;s wort should be given cautiously. This interaction is presumed to be related to inhibition of the metabolism of vincristine sulphate.</p><p>&nbsp;</p><p>Concomitant administration of azole antifungals (e.g., itraconazole, voriconazole, posaconazole, isavuconazole and fluconazole) with vincristine may increase the plasma concentrations of vincristine, which can lead to an early onset and/or increased severity of neurotoxicity and other side effects (see section 4.4). Therefore, azole antifungals should be used with caution in patients receiving vincristine and should only be used when there are no alternative antifungal treatment options available or when the potential benefits outweigh the risks of the combination. Patients should be closely monitored for adverse effects with concomitant use.</p><p>Although not studied in vitro or in vivo, voriconazole may increase the plasma concentrations of the vinca alkaloids including vincristine sulphate and lead to neurotoxicity. Therefore, it is recommended that dose adjustment of vincristine sulphate be considered.</p><p>&nbsp;</p><p><u>L-asparaginase</u></p><p>When vincristine sulphate is used in combination with L-asparaginase, it should be given 12 to 24 hours before administration of the enzyme in order to minimise toxicity, since administering L-asparaginase first may reduce hepatic clearance of vincristine sulphate.</p><p>&nbsp;</p><p><u>Radiation therapy</u></p><p>When chemotherapy is being given in conjunction with radiation therapy through portals which include the liver, the use of vincristine sulphate should be delayed until radiation therapy has been completed.</p><p>&nbsp;</p><p><u>Methotrexate</u></p><p>Vincristine sulphate appears to increase the cellular uptake of methotrexate by malignant cells and this principle has been applied in high-dose methotrexate therapy.</p><p>&nbsp;</p><p><u>Dactinomycin</u></p><p>Severe hepatotoxicity, including veno-occlusive disease has been reported in patients treated with a combination of vincristine sulphate and dactinomycin for renal carcinoma.</p><p>&nbsp;</p><p><u>Live vaccines&nbsp; </u></p><p>Concomitant use of vincristine sulphate with a live virus vaccine may potentiate the replication of the virus and increase the adverse reactions of the vaccine virus and/or reduce the antibody response of the patient to the vaccine itself because normal defense mechanisms can be suppressed by treatment with vincristine sulphate. Immunisation of such patients should be performed with extreme caution, and only after a thorough evaluation of the haematological picture and with the consent of the doctor who is carrying out the vincristine sulphate therapy. The lapse of time between the suspension of the drug that causes immunosuppression and the recovery of the patient&rsquo;s capacity to respond to the vaccine depends on many different factors and is estimated to vary from a period of 3 months to 1 year.</p><p>&nbsp;</p><p><u>Granulocyte-colony stimulating factors (G-CSFs) </u></p><p>G-CSFs such as filgrastim and pegfilgrastim should be administered at least 24 hours after receiving cytotoxic chemotherapy including vincristine sulphate, because of increased risk of myelosuppression.</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in males and females</u></p><p>Women of childbearing potential should be advised to avoid becoming pregnant while receiving vincristine sulphate. Due to the potential for genotoxicity, teratogenicity, and embryo toxicity, female patients of reproductive potential are advised to use highly effective contraception during treatment and for at least 7 months following last dose of vincristine sulphate.</p><p>&nbsp;</p><p>Due to the potential for genotoxicity, male patients with female partners of reproductive potential are advised to use highly effective contraception during treatment and for at least 4 months following the last dose of vincristine sulphate.</p><p>&nbsp;</p><p><u>Pregnancy</u><br />Caution is necessary with the use of all oncolytic drugs during pregnancy. Both men and women receiving vincristine sulphate should be informed of the potential risk of adverse effects. Reliable methods of contraception or abstinence are recommended.</p><p>&nbsp;</p><p>Vincristine sulphate can cause foetal harm following maternal or paternal exposure, although there are no adequate and well-controlled studies. Studies in animals have shown vincristine sulphate can induce teratogenic effects as well as embryolethality (see section 5.3).</p><p>&nbsp;</p><p>If vincristine sulphate is used during pregnancy or if the patient becomes pregnant while receiving this medicinal product she should be informed of the potential hazard to the foetus.</p><p>&nbsp;</p><p>There are no or limited amount of data from the use of vincristine sulphate in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3.)</p><p>&nbsp;</p><p><u>Breast-feeding </u></p><p>There is insufficient information on the excretion of vincristine sulphate in human breast milk. Because of the potential for serious adverse reactions due to vincristine sulphate in nursing infants, the mother should be advised not to breast-feed while on vincristine sulphate therapy and for 1 month following last dose of treatment or to discontinue/abstain from vincristine sulphate therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Based on clinical reports, male and female fertility may be compromised (see section&nbsp;4.4). It is recommended to discuss fertility preservation with men and women prior to treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In general, adverse reactions are reversible and are related to dosage size and cumulative dosage. The use of small amounts of vincristine daily for long periods is not advised. The most common adverse reaction is alopecia; the most troublesome adverse reactions are neuromuscular in origin.</p><p>&nbsp;</p><p>When single weekly doses of vincristine sulphate are employed, the adverse reactions of granulocytopenia, neuritic pain, and constipation are usually of short duration (i.e. less than 7 days). When the dosage is reduced, these reactions may lessen or disappear. They seem to be increased when the calculated amount of medicinal product is given in divided doses. Other adverse reactions, such as alopecia, sensory loss, paraesthesia, difficulty in walking, slapping gait, loss of deep-tendon reflexes and muscle wasting may persist for at least as long as therapy is continued. Generalised sensorimotor dysfunction may become progressively more severe with continued treatment, but the neuromuscular difficulties may persist for prolonged periods in some patients. Re-growth of hair may occur while maintenance therapy continues.</p><p>&nbsp;</p><p>The reported adverse reactions are listed below by MedDRA system Organ Class and by frequency. Frequencies are defined as: Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very rare (&lt;1/10,000), and Frequency not known (cannot be estimated from available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very Common</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Frequency not known</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infection, Sepsis, Neutropenic sepsis</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Secondary malignancies</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Thrombocytopenia<sup>a</sup>, Anaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Granulocytopenia, Neutropenia, Haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction<sup>b</sup>, Oedema<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Inappropriate antidiuretic hormone secretion<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperuricaemia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders<sup>d</sup></p></td><td style="vertical-align:top"><p>Peroneal nerve palsy, Paraesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Coma</p></td><td style="vertical-align:top"><p>Paralysis, Seizure<sup>e</sup>, Cranial nerve palsies multiple<sup>f</sup>, Sensory loss, Areflexia, Neuralgia, Nystagmus, Ataxia, Balance disorder, Gait disturbance, Dizziness, Headache, Paresis, Motor dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blindness transient, Optic atrophy<sup>g</sup></p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Deafness<sup>h</sup>, Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocardial infarction<sup>i</sup>, Coronary artery disease<sup>i</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension, Hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oropharyngeal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute respiratory distress syndrome,</p><p>Bronchospasm, Dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Constipation<sup>j</sup>, Abdominal pain, Vomiting, Nausea</p></td><td style="vertical-align:top"><p>Paralytic ileus<sup>k</sup>, Diarrhoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Intestinal perforation,</p><p>Gastrointestinal necrosis,</p><p>Mouth ulceration,</p><p>Salivary gland pain</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Venoocclusive liver disease<sup>l</sup></p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal, connective tissue and bone disorders</p></td><td style="vertical-align:top"><p>Myalgia,</p><p>Bone pain</p></td><td style="vertical-align:top"><p>Pain in jaw</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle atrophy, Pain in extremity,</p><p>Back pain</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urinary retention<sup>m</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Polyuria,</p><p>Dysuria,</p><p>Atonic urinary bladder</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia,</p><p>Injection site reaction (see section 4.2)</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight decrease</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>a. If thrombocytopenia is present when treatment begins, it may actually improve before the appearance of marrow remission.</p><p>b. Reported in patients receiving vincristine sulphate as part of a multi-drug chemotherapy regimen.</p><p>c. There is a high urinary sodium excretion in the presence of hyponatraemia, renal or adrenal disease, hypotension, dehydration, azotaemia and clinical oedema are absent. With fluid deprivation, improvement occurs in the hyponatraemia and in the renal loss of sodium.</p><p>d. Often dose limiting.</p><p>e. Frequently with hypertension. Several instances of convulsions followed by coma have been reported in children.</p><p>f. Especially affecting the extra-ocular and laryngeal muscles.</p><p>g. With blindness.</p><p>h. Partial or total, temporary or permanent. Manifestations also include difficulties with balance, including dizziness, nystagmus and vertigo. Particular caution is warranted when vincristine sulphate is used in combination with other agents known to be ototoxic, such as platinum-based drugs.</p><p>i. Reported in association with chemotherapy combinations that included vincristine sulphate when given to patients previously treated with mediastinal radiation. Causality has not been established.</p><p>j. Constipation may take the form of upper colon impaction and the rectum may be found to be empty on physical examination.</p><p>k. Paralytic ileus may occur particularly in young children. The ileus will reverse itself upon temporary discontinuance of vincristine sulphate and with symptomatic care.</p><p>l. Especially in children.</p><p>m. Other drugs known to cause urinary retention (particularly in the elderly) should, if possible, be discontinued for the first few days following administration of vincristine sulphate.</p><p>&nbsp;</p><p><em>Neoplasms benign, malignant and unspecified </em><em>(including cysts and polyps): </em>The occurrence of secondary malignancies has been reported rarely in patients treated with vincristine sulphate in association with other anticancer drugs known to be carcinogenic.</p><p>&nbsp;</p><p><em>Blood and lymphatic system disorders</em>: Granulocytopenia and neutropenia; vincristine does not appear to have any constant or significant effect upon the platelets or the red blood cells, however, anaemia, haemolytic anaemia and thrombocytopenia have been reported. Clinical consequences of granulocytopenia may be fever, infections and sepsis. There have been occasional reports of fatal infections during vincristine therapy.</p><p>&nbsp;</p><p><em>Nervous system disorders</em>: Frequently, there appears to be a sequence in the development of neuromuscular side effects. Initially, one may encounter only sensory impairment and paraesthesia. With continued treatment, neuritic pain may appear and later, motor difficulties. No reports have yet been made of any agent that can reverse the neuromuscular manifestations of vincristine sulphate.</p><p><em>&nbsp;</em></p><p><em>Ear and labyrinth disorders: </em>Treatment with vinca alkaloids has resulted rarely in both vestibular and auditory damage to the eighth cranial nerve.</p><p><em>&nbsp;</em></p><p><em>Gastro-intestinal disorders</em>: The constipation which may be encountered responds well to such usual measures as enemas and laxatives.&nbsp; Colicky abdominal pain, coupled with an empty rectum, may mislead the clinician. A flat film of the abdomen is useful in demonstrating this condition. A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine sulphate.</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions </strong></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Center (NPC).</p><p>&nbsp;</p><p><u>To report any side effect:</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In general, adverse reactions are reversible and are related to dosage size and cumulative dosage. The use of small amounts of vincristine daily for long periods is not advised. The most common adverse reaction is alopecia; the most troublesome adverse reactions are neuromuscular in origin.</p><p>&nbsp;</p><p>When single weekly doses of vincristine sulphate are employed, the adverse reactions of granulocytopenia, neuritic pain, and constipation are usually of short duration (i.e. less than 7 days). When the dosage is reduced, these reactions may lessen or disappear. They seem to be increased when the calculated amount of medicinal product is given in divided doses. Other adverse reactions, such as alopecia, sensory loss, paraesthesia, difficulty in walking, slapping gait, loss of deep-tendon reflexes and muscle wasting may persist for at least as long as therapy is continued. Generalised sensorimotor dysfunction may become progressively more severe with continued treatment, but the neuromuscular difficulties may persist for prolonged periods in some patients. Re-growth of hair may occur while maintenance therapy continues.</p><p>&nbsp;</p><p>The reported adverse reactions are listed below by MedDRA system Organ Class and by frequency. Frequencies are defined as: Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very rare (&lt;1/10,000), and Frequency not known (cannot be estimated from available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very Common</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Frequency not known</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infection, Sepsis, Neutropenic sepsis</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Secondary malignancies</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Thrombocytopenia<sup>a</sup>, Anaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Granulocytopenia, Neutropenia, Haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction<sup>b</sup>, Oedema<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Inappropriate antidiuretic hormone secretion<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperuricaemia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders<sup>d</sup></p></td><td style="vertical-align:top"><p>Peroneal nerve palsy, Paraesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Coma</p></td><td style="vertical-align:top"><p>Paralysis, Seizure<sup>e</sup>, Cranial nerve palsies multiple<sup>f</sup>, Sensory loss, Areflexia, Neuralgia, Nystagmus, Ataxia, Balance disorder, Gait disturbance, Dizziness, Headache, Paresis, Motor dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blindness transient, Optic atrophy<sup>g</sup></p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Deafness<sup>h</sup>, Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocardial infarction<sup>i</sup>, Coronary artery disease<sup>i</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension, Hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oropharyngeal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute respiratory distress syndrome,</p><p>Bronchospasm, Dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Constipation<sup>j</sup>, Abdominal pain, Vomiting, Nausea</p></td><td style="vertical-align:top"><p>Paralytic ileus<sup>k</sup>, Diarrhoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Intestinal perforation,</p><p>Gastrointestinal necrosis,</p><p>Mouth ulceration,</p><p>Salivary gland pain</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Venoocclusive liver disease<sup>l</sup></p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal, connective tissue and bone disorders</p></td><td style="vertical-align:top"><p>Myalgia,</p><p>Bone pain</p></td><td style="vertical-align:top"><p>Pain in jaw</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle atrophy, Pain in extremity,</p><p>Back pain</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urinary retention<sup>m</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Polyuria,</p><p>Dysuria,</p><p>Atonic urinary bladder</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia,</p><p>Injection site reaction (see section 4.2)</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight decrease</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>a. If thrombocytopenia is present when treatment begins, it may actually improve before the appearance of marrow remission.</p><p>b. Reported in patients receiving vincristine sulphate as part of a multi-drug chemotherapy regimen.</p><p>c. There is a high urinary sodium excretion in the presence of hyponatraemia, renal or adrenal disease, hypotension, dehydration, azotaemia and clinical oedema are absent. With fluid deprivation, improvement occurs in the hyponatraemia and in the renal loss of sodium.</p><p>d. Often dose limiting.</p><p>e. Frequently with hypertension. Several instances of convulsions followed by coma have been reported in children.</p><p>f. Especially affecting the extra-ocular and laryngeal muscles.</p><p>g. With blindness.</p><p>h. Partial or total, temporary or permanent. Manifestations also include difficulties with balance, including dizziness, nystagmus and vertigo. Particular caution is warranted when vincristine sulphate is used in combination with other agents known to be ototoxic, such as platinum-based drugs.</p><p>i. Reported in association with chemotherapy combinations that included vincristine sulphate when given to patients previously treated with mediastinal radiation. Causality has not been established.</p><p>j. Constipation may take the form of upper colon impaction and the rectum may be found to be empty on physical examination.</p><p>k. Paralytic ileus may occur particularly in young children. The ileus will reverse itself upon temporary discontinuance of vincristine sulphate and with symptomatic care.</p><p>l. Especially in children.</p><p>m. Other drugs known to cause urinary retention (particularly in the elderly) should, if possible, be discontinued for the first few days following administration of vincristine sulphate.</p><p>&nbsp;</p><p><em>Neoplasms benign, malignant and unspecified </em><em>(including cysts and polyps): </em>The occurrence of secondary malignancies has been reported rarely in patients treated with vincristine sulphate in association with other anticancer drugs known to be carcinogenic.</p><p>&nbsp;</p><p><em>Blood and lymphatic system disorders</em>: Granulocytopenia and neutropenia; vincristine does not appear to have any constant or significant effect upon the platelets or the red blood cells, however, anaemia, haemolytic anaemia and thrombocytopenia have been reported. Clinical consequences of granulocytopenia may be fever, infections and sepsis. There have been occasional reports of fatal infections during vincristine therapy.</p><p>&nbsp;</p><p><em>Nervous system disorders</em>: Frequently, there appears to be a sequence in the development of neuromuscular side effects. Initially, one may encounter only sensory impairment and paraesthesia. With continued treatment, neuritic pain may appear and later, motor difficulties. No reports have yet been made of any agent that can reverse the neuromuscular manifestations of vincristine sulphate.</p><p><em>&nbsp;</em></p><p><em>Ear and labyrinth disorders: </em>Treatment with vinca alkaloids has resulted rarely in both vestibular and auditory damage to the eighth cranial nerve.</p><p><em>&nbsp;</em></p><p><em>Gastro-intestinal disorders</em>: The constipation which may be encountered responds well to such usual measures as enemas and laxatives.&nbsp; Colicky abdominal pain, coupled with an empty rectum, may mislead the clinician. A flat film of the abdomen is useful in demonstrating this condition. A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine sulphate.</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions </strong></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Center (NPC).</p><p>&nbsp;</p><p><u>To report any side effect:</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agent - vinca alkaloid. ATC Code:&nbsp; L01C A02</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Vincristine sulphate is an antineoplastic drug with broad-spectrum anti-tumor activity in man.&nbsp; The drug may act by mitotic inhibition, causing an arrest of cell division in metaphase. The drug is relatively marrow-sparing and is thus suitable for use in combination with other cancer chemotherapeutic agents.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vincristine sulphate is poorly absorbed orally. The clearance of the drug after rapid intravenous injection follows a triphasic decay pattern: a very rapid steep descent (alpha phase); a narrow-middle region (beta-phase) and a much longer terminal region (gamma phase). The terminal phase half-life of the drug varies from 15-155 hours.&nbsp;</p><p>&nbsp;</p><p>Dosing with the drug more frequently than once weekly is therefore probably unnecessary.&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vincristine sulphate is primarily excreted by the biliary route.&nbsp;</p><p>&nbsp;</p><p>Patients with impaired hepatic or biliary function, as evidenced by a raised serum alkaline phosphatase, have been shown to have a significantly prolonged vincristine sulphate elimination half-life.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Both <em>in vivo</em> and <em>in vitro</em> laboratory tests have failed to demonstrate conclusively that this product is mutagenic. No evidence of carcinogenicity was found following intraperitoneal administration in rats and mice, although this study was limited.&nbsp;</p><p>&nbsp;</p><p>In several animal species, vincristine sulphate can include teratogenic effects, as well as embryo lethality, with doses that are non-toxic to the pregnant animal. Mice treated with a single IP administration of 0.25 to 0.35&nbsp;mg/kg, vincristine sulphate on day 9 of pregnancy, showed foetal resorption rates of 49% to 57% (control: 6%) and 32% to 66% of surviving foetuses showed malformations.</p><p><strong>&nbsp;</strong></p><p>As a classic tubulin binder, the primary mode of action of vincristine is aneugenicity, but at higher doses and over prolonged dosing intervals, the expression of clastogenicity becomes a possibility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>It is not recommended that vincristine sulphate should be mixed with any other drug and should not be diluted in solutions that raise or lower the pH outside the range 3.5 to 5.5. It should not be mixed with anything other than normal saline or 5% glucose solution.</p><p>&nbsp;</p><p>Furosemide both in syringe and injected sequentially into Y-site with no flush between, results in immediate precipitation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.

Do not use Vincristine sulphate after the expiry date which is stated on the Vial label after EXP: The expiry date refers to the last day of that month.

Chemical and physical in-use stability has been demonstrated for up to 24 hours at 2 – 8 °C and at 25 °C when Vincristine Sulphate injection is diluted with 0.9% sodium chloride solution or 5% glucose solution in infusion bags and protected from light. If stored under normal light at 25 °C, when diluted with 0.9% sodium chloride solution or 5% glucose solution, the diluted product is stable for 8 hours or 4 hours respectively.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 – 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&ordm;C &ndash; 8 &ordm;C).</p><p>Keep the vial in the outer carton, in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after first opening and dilution, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1 ml presentation contains 1 mg of vincristine sulphate.</p><p>&nbsp;</p><p>1 ml or 2 ml Type I clear glass vials, with rubber closures and aluminium caps in packs of 5 vials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Cytotoxic Handling Guidelines</strong></p><p><strong>&nbsp;</strong></p><p><strong>Administration:</strong></p><p><strong>&nbsp;</strong></p><p>Should be administered only by or under the direct supervision of a qualified physician who is experienced in the use of cancer chemotherapeutic agents.</p><p>&nbsp;</p><p>Vincristine sulphate can be diluted with sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection or glucose 50&nbsp;mg/ml (5%) solution for injection, see section 6.3.</p><p>&nbsp;</p><p><strong>Preparation (Guidelines)</strong></p><p><strong>&nbsp;</strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chemotherapeutic agents should be prepared for administration only by professionals who have been trained in the safe use of preparation.</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operations such as reconstitution of powder and transfer to syringes should be carried out only in the designated area. The work surface should be covered with disposable plastic-backed absorbent paper.</p><p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The personnel carrying out these procedures should be adequately protected with clothing, masks, gloves and eye shield.</p><p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnant personnel are advised not to handle chemotherapeutic agents.</p><p>&nbsp;</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Luer-lock fittings on all syringes and sets. Large bore needles are recommended to minimise the pressure and the possible formation of aerosols. The latter may be reduced by the use of a venting needle.</p><p>&nbsp;</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not add extra fluid to the vial prior to removal of the dose. Withdraw the solution of vincristine sulphate into an accurate syringe, measuring the dose carefully. Do not add extra fluid to the vial in an attempt to empty it completely.</p><p>&nbsp;</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adequate care and precaution should be taken in the disposal of items (syringes, needles, etc.) used to reconstitute cytotoxic drugs.</p><p>&nbsp;</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Whenever solution and container permit, parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.</p><p>&nbsp;</p><p><strong>Contamination</strong></p><p><strong>&nbsp;</strong></p><p>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Precautions should be taken to avoid the drug accidentally coming into contact with the eyes. If accidental contamination occurs, severe irritation (or if the drug was delivered under pressure, even corneal ulceration) may result. In the event of contact with the skin or eyes, the affected area should be washed with copious amounts of water or normal saline thoroughly and immediately.&nbsp; A bland cream may be used to treat the transient stinging of skin.&nbsp; Medical advice should be sought if the eyes are affected.</p><p>&nbsp;</p><p>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event of spillage, operators should put on gloves and mop the spilled material with a sponge kept in the area for that purpose.&nbsp; Rinse the area twice with water.&nbsp; Put all solutions and sponges into a plastic bag and then seal it.</p><p>&nbsp;</p><p><strong>Disposal</strong></p><p><strong>&nbsp;</strong></p><p>Syringes, containers, absorbent materials, solution and any other contaminated material should be placed in a thick plastic bag or other impervious container and incinerated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hospira UK Limited
United Kingdom

MANUFACTURER 
Hospira Australia Pty Ltd, MULGRAVE, Australia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>